HeartMate 3左心室辅助装置流出道人工血管狭窄
单中心回顾性队列研究纳入2014年11月至2019年7月接受HeartMate 3左心室辅助装置的患者165例,其中46例(28%)有合格影像学检查。33%(15/46)存在流出道人工血管狭窄,狭窄与左心室辅助装置支持时间更长显著相关(588.2±277.5天 vs 131.5±170.9天,P<.0001)。识别狭窄后1年生存率为93%,伴与不伴狭窄患者的左心室卸载无显著差异(16.7% vs 17.7%,P=.86)。
要点
- 在影像质量合格的患者中,33%(15/46)存在HeartMate 3流出道人工血管狭窄。
- 流出道人工血管狭窄与左心室辅助装置支持时间更长显著相关(588.2±277.5天 vs 131.5±170.9天,P<.0001)。
- 伴与不伴狭窄患者的左心室卸载无显著差异(16.7% vs 17.7%,P=.86)。
核心结论
- 在影像质量合格的患者中,三分之一有流出道人工血管狭窄的证据。
- 继发于生物碎屑的流出道人工血管狭窄在左心室辅助装置支持时间更长的HeartMate 3受体中更可能被发现。
- 伴与不伴狭窄患者的左心室卸载无显著差异。
研究设计与样本
- 单中心回顾性队列研究,纳入2014年11月至2019年7月接受HeartMate 3左心室辅助装置的患者。
- 纳入所有具有足以评估流出道人工血管管腔的计算机断层扫描血管造影或静脉造影剂计算机断层扫描的患者。
- 165例HeartMate 3左心室辅助装置受体中,46例(28%)有合格影像学检查。
- 狭窄定义为低密度影≥3 mm。
主要发现
- 33%(15/46)存在流出道人工血管狭窄。
- 1例患者完全梗阻需急诊手术,14例患者低密度影中位数为4.5 mm(四分位距3.3-5.8 mm)。
- 流出道人工血管狭窄的存在与左心室辅助装置支持时间更长显著相关(588.2±277.5天 vs 131.5±170.9天;P<.0001)。
- 识别狭窄后1年生存率为93%,1例完全梗阻患者死亡。
- 左心室卸载(计算机断层扫描成像时左心室舒张末期内径较左心室辅助装置前的平均百分比下降)在伴与不伴狭窄患者中分别为16.7%与17.7%(P=.86)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with the HeartMate 3 (HM3, Abbott) left ventricular (LV) assist device (LVAD), outflow graft narrowing has been reported as a result of accumulation of biodebris either internal or external to the graft. This study describes the prevalence, imaging findings, and clinical outcomes associated with HM3 LVAD outflow graft narrowing. METHODS: A single-center retrospective cohort study was performed in patients who received an HM3 LVAD between November 2014 and July 2019. All patients with a computed tomographic (CT) angiogram or a CT scan with intravenous contrast sufficient to evaluate the outflow graft lumen were included. Narrowing was defined as a hypodensity of ≥3 mm. RESULTS: Of 165 HM3 LVAD recipients, 46 (28%) had qualifying imaging. Outflow graft narrowing was present in 33% (15/46). One patient had complete obstruction requiring emergency surgery, whereas 14 patients had a median hypodensity of 4.5 mm (interquartile range, 3.3-5.8 mm). The presence of outflow graft narrowing was significantly associated with a longer duration of LVAD support (588.2 ± 277.5 days vs 131.5 ± 170.9 days; P < .0001). One-year survival after identification of narrowing was 93%, with death occurring in 1 patient with complete obstruction. LV unloading (mean percent decrease in LV end-diastolic diameter at time of CT imaging vs pre-LVAD) was 16.7% vs 17.7% in patients with and without narrowing, respectively (P = .86). CONCLUSIONS: Among patients with adequate imaging, one-third have evidence of narrowing. Outflow graft narrowing secondary to biodebris was more likely to be found in HM3 LVAD recipients with longer duration of LVAD support. There was no significant difference in LV unloading between patients with and without narrowing.
引用
- Jain SS, Clerkin KJ, Anstey DE, et al. Outflow Graft Narrowing of the HeartMate 3 Left Ventricular Assist Device. Ann Thorac Surg. 2022. PMID: 34998738. doi:10.1016/j.athoracsur.2021.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。